NeoImmuneTech (NIT), along with its parent company Genexine, has signed an agreement with Roche to perform a Phase Ib/IIa immuno-oncology trial evaluating HyLeukin-7 (IL-7-hyFc) in combination with Tecentriq (atezolizumab) to treat advanced high-risk skin cancers.

The proposed multi-centre open-label trial will cover three cancer types, including melanoma, Merkel cell carcinoma and cutaneous squamous cell carcinoma.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial will be led by NIT and the Immune Oncology Network (ION), and will aim to investigate safety and anti-tumour activity of HyLeukin-7 in combination with Tecentriq in around 70 patients with anti-PD-(L)1 naïve or refractory high-risk skin cancers.

“HyLeukin-7 has shown in multiple studies to substantially increase the total body complement of T cells with little toxicity.”

The trial is expected to begin by the second half of this year and will be conducted across the US and possibly additional countries.

Fred Hutchinson Cancer Research Center Immune Oncology Network director Martin Cheever said: “HyLeukin-7 has shown in multiple studies to substantially increase the total body complement of T cells with little toxicity.

“HyLeukin-7 is designed to be effective when used in concert with a variety of different immunotherapy regimens, including the combination with anti-PD-(L)1 that is being tested in this trial.”

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

HyLeukin-7 is a T cell amplifier, featuring a covalently linked homodimer of engineered Interleukin-7 (IL-7) molecule, biologically fused with the proprietary long-acting platform hyFc.

The solution is currently under development as an ‘IO enabling’ therapy to harness T cell immunity in combination with other cancer treatments, especially with anti-PD-(L)1 agents or chemo/radiotherapy.

Tecentriq (atezolizumab), a registered product of Roche Group member Genentech, is a PD-L1 checkpoint inhibitor.